Drug and exercise combo may boost walking in MS

NCT ID NCT06136728

Recruiting now Symptom relief Sponsor: MGH Institute of Health Professions Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests whether taking dalfampridine (a drug that helps some people with MS walk faster) along with physical therapy improves mobility more than either treatment alone. Forty-eight adults with MS will first take the drug for 6 weeks, then stop for 2 weeks, and then be randomly assigned to 6 weeks of physical therapy either with or without the drug. Researchers will measure walking speed and balance to see if the combination works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalfampridine (Ampyra)
What this could lead to: If it works, this could point toward a better way to improve walking and balance in people with multiple sclerosis by combining medication with physical therapy.
What could go wrong: This is a small early-phase trial with only 48 people, so results may not apply to everyone. The medication can cause side effects like dizziness or seizures, and the combination may not prove better than therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

MGH Institute of Health Professions
RECRUITING

Boston, Massachusetts, 02129, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.